Literature DB >> 33668591

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.

Mingming Song1, Chang Liu1, Siyu Chen1, Wenxiang Zhang1.   

Abstract

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

Entities:  

Keywords:  combination therapy; drug delivery systems; gene therapy; immunotherapy; melanoma; photodynamic therapy

Mesh:

Substances:

Year:  2021        PMID: 33668591      PMCID: PMC7918190          DOI: 10.3390/ijms22041873

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  188 in total

1.  Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Authors:  Jessie Villanueva; Jeffrey R Infante; Clemens Krepler; Patricia Reyes-Uribe; Minu Samanta; Hsin-Yi Chen; Bin Li; Rolf K Swoboda; Melissa Wilson; Adina Vultur; Mizuho Fukunaba-Kalabis; Bradley Wubbenhorst; Thomas Y Chen; Qin Liu; Katrin Sproesser; Douglas J DeMarini; Tona M Gilmer; Anne-Marie Martin; Ronen Marmorstein; David C Schultz; David W Speicher; Giorgos C Karakousis; Wei Xu; Ravi K Amaravadi; Xiaowei Xu; Lynn M Schuchter; Meenhard Herlyn; Katherine L Nathanson
Journal:  Cell Rep       Date:  2013-09-19       Impact factor: 9.423

2.  Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.

Authors:  Jessica Ruzzolini; Silvia Peppicelli; Elena Andreucci; Francesca Bianchini; Francesca Margheri; Anna Laurenzana; Gabriella Fibbi; Nicola Pimpinelli; Lido Calorini
Journal:  Cancer Lett       Date:  2017-08-18       Impact factor: 8.679

3.  Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses.

Authors:  Chenguang Wang; Yukun Guan; Mengze Lv; Rui Zhang; Zhaoying Guo; Xiaoming Wei; Xiaoxia Du; Jing Yang; Tong Li; Yi Wan; Xiaodong Su; Xiaojun Huang; Zhengfan Jiang
Journal:  Immunity       Date:  2018-04-10       Impact factor: 31.745

4.  Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.

Authors:  Shiqi Huang; Yicong Zhang; Luyao Wang; Wei Liu; Linyu Xiao; Qing Lin; Tao Gong; Xun Sun; Qin He; Zhirong Zhang; Ling Zhang
Journal:  J Control Release       Date:  2020-04-03       Impact factor: 9.776

5.  Activatable Polymer Nanoenzymes for Photodynamic Immunometabolic Cancer Therapy.

Authors:  Ziling Zeng; Chi Zhang; Jingchao Li; Dong Cui; Yuyan Jiang; Kanyi Pu
Journal:  Adv Mater       Date:  2020-12-11       Impact factor: 30.849

6.  May melanophages hinder the subclinical spread of lentigo maligna and lentigo maligna melanoma? Results from a pilot study.

Authors:  R Moro; C Requena; E Ríos-Viñuela; E Manrique-Silva; V Traves; P G Calzavara-Pinton; G Gualdi; E Nagore
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-02-09       Impact factor: 6.166

Review 7.  Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors.

Authors:  Anja Derer; Benjamin Frey; Rainer Fietkau; Udo S Gaipl
Journal:  Cancer Immunol Immunother       Date:  2015-11-21       Impact factor: 6.968

8.  PEGylated WS2 nanodrug system with erythrocyte membrane coating for chemo/photothermal therapy of cervical cancer.

Authors:  Ying Long; Xianjin Wu; Zhen Li; Jialong Fan; Xing Hu; Bin Liu
Journal:  Biomater Sci       Date:  2020-08-19       Impact factor: 6.843

9.  A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice.

Authors:  Jing Lu; Guoliang Lu; Shudan Tan; Jia Xia; Hualong Xiong; Xiaofei Yu; Qingqing Qi; Xiang Yu; Li Li; Hang Yu; Ningshao Xia; Tianying Zhang; Yingjie Xu; Jinzhong Lin
Journal:  Cell Res       Date:  2020-08-17       Impact factor: 25.617

10.  Hybrid, metal oxide-peptide amphiphile micelles for molecular magnetic resonance imaging of atherosclerosis.

Authors:  Christopher Poon; Juan Gallo; Johan Joo; Timothy Chang; Manuel Bañobre-López; Eun Ji Chung
Journal:  J Nanobiotechnology       Date:  2018-11-15       Impact factor: 10.435

View more
  4 in total

Review 1.  Nanoparticle-Based Combination Therapy for Melanoma.

Authors:  Hongbo Chen; Kai Hou; Jing Yu; Le Wang; Xue Chen
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

Review 2.  Magnetic nanoparticles in theranostics of malignant melanoma.

Authors:  Maxim Shevtsov; Susanne Kaesler; Christian Posch; Gabriele Multhoff; Tilo Biedermann
Journal:  EJNMMI Res       Date:  2021-12-14       Impact factor: 3.138

3.  One-Pot Synthesis of Amphiphilic Biopolymers from Oxidized Alginate and Self-Assembly as a Carrier for Sustained Release of Hydrophobic Drugs.

Authors:  Zhaowen Liu; Xiuqiong Chen; Zhiqin Huang; Hongcai Wang; Shirui Cao; Chunyang Liu; Huiqiong Yan; Qiang Lin
Journal:  Polymers (Basel)       Date:  2022-02-11       Impact factor: 4.329

4.  Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond.

Authors:  Joanna Bojarska; Martin Breza; Milan Remko; Malgorzata Czyz; Anna Gajos-Michniewicz; Michał Zimecki; Krzysztof Kaczmarek; Izabela D Madura; Jakub M Wojciechowski; Wojciech M Wolf
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.